What is IMI-PainCare?





Pain is one of the major factors that influence quality-of-life and hence its management is essential for all medical conditions. Prevalence rates of chronic pain vary between 11% and 40% (1). About 50% of patients report moderate-severe acute postoperative pain and between 2-10% of patients develop chronic post-surgical pain (2).

"Improving the care of patients suffering from acute or chronic pain"

is the goal of the IMI-PainCare Consortium, composed of 41 participants from 14 countries.

IMI-PainCare is centered around 3 subprojects:

PROMPT wants to define a Core Outcome Set for different pain indications and encourages the use of patient reported outcome measures to improve management and research of acute and chronic pain.

Within the **BioPain** subproject biomarkers for pain signaling in the nervous system are pharmacologically validated in healthy subjects and in animals.

Chronic pelvic pain is the focus of the subproject **TRiPP** and aims at improving the translation of laboratory and clinical findings into treatment.



(1) Dahlhamer J, Lucas J, Zelaya C, et al. Prevalence of chronic pain and high-impact chronic pain among adults - United States, 2016. MMWR Morb Mortal Wkly Rep 2018; 67: 1001–06. (2) Fletcher D, Stamer U, Pogatzki-Zahn E, Zaslansky R, Tanase NV, Perruchoud C, Kranke P, Komann M, Lehman T, euCPSP group for the Clinical Trial Network group of the European Society of Anaesthesiology, Meissner W. A European Observational Study on Chronic Postsurgical Pain – EuCPSP. EJA 2015;32: 725-34



Learn more at: www.imi-paincare.eu



This work has received support from the EU/EFPIA/Innovative Medicines Initiative [2] Joint Undertaking (IMI-PAINCARE) grant No 777500. The statements and opinions presented here reflect the author's view and neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained therein.